The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults.
VaccineSep 5, 2026 (epub)
McLeod C, M Dymock, K L Flanagan et al.
✦ AI-curated · Sources linked
In 30 seconds
The PICOBOO trial evaluated the reactogenicity of nine licensed COVID-19 vaccines in immunocompetent adults aged over 12 years. This randomized controlled trial involved 586 participants and found that local reactions occurred in 75% of doses and systemic reactions in 76%. Notably, severe reactogenicity events were rare.
Key findings
- Local reactions were reported after 786 (75%) doses administered.
- Systemic reactions occurred after 798 (76%) doses.
- Local reactogenicity ranged from 47% with NVX-CoV2373 to 90% with Moderna.
- Severe reactogenicity events were rare.
Why it matters
Understanding the reactogenicity of COVID-19 vaccines is crucial for clinicians to inform patients about potential side effects and to manage expectations regarding vaccination experiences.